Compare GAU & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GAU | TECX |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | Canada | United States |
| Employees | N/A | 60 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.0M | 549.5M |
| IPO Year | 2006 | N/A |
| Metric | GAU | TECX |
|---|---|---|
| Price | $1.98 | $37.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.08 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 3.9M | 128.2K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $82.77 | N/A |
| Revenue Next Year | $29.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $14.39 |
| 52 Week High | $3.62 | $35.99 |
| Indicator | GAU | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 73.51 |
| Support Level | $1.96 | $27.31 |
| Resistance Level | $2.75 | N/A |
| Average True Range (ATR) | 0.10 | 2.07 |
| MACD | -0.00 | 0.62 |
| Stochastic Oscillator | 34.68 | 92.97 |
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.